Compounds > cefadroxil
Page last updated: 2024-12-06

cefadroxil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

uvaricin: isolated from Uvaria accuminata; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID441645
CHEBI ID9916
SCHEMBL ID5881208
MeSH IDM0003714

Synonyms (12)

Synonym
ygw6mn47bb ,
uvaricin
chebi:9916 ,
[(1s)-1-[(2r,5r)-5-[(2r,5r)-5-[(1r)-1-hydroxy-13-[(2s)-2-methyl-5-oxo-2h-furan-4-yl]tridecyl]oxolan-2-yl]oxolan-2-yl]undecyl] acetate
SCHEMBL5881208
Q2481797
2(5h)-furanone, 3-((13r)-13-((2r,2r,5r,5r)-5-((1s)-1-(acetyloxy)undecyl)octahydro(2,2-bifuran)-5-yl)-13-hydroxytridecyl)-5-methyl-, (5s)-
2(5h)-furanone, 3-(13-(5-(1-(acetyloxy)undecyl)octahydro(2,2-bifuran)-5-yl)-13-hydroxytridecyl)-5-methyl-, (2r-(2.alpha.(2r*,5r*(s*)),5.beta.(r*(s*))))-
(+)-uvaricin
(1s)-1-[(2r,2'r,5r,5'r)-5'-[(1r)-1-hydroxy-13-[(5s)-5-methyl-2-oxo-2,5-dihydrofuran-3-yl]tridecyl]-[2,2'-bioxolan]-5-yl]undecyl acetate
145165-09-9
DTXSID501043967
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
polyketideNatural and synthetic compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations, etc. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID340563Antitumor activity against mouse P388 cells in at 1.4 mg/kg by in vivo 3PS assay2008Journal of natural products, Jul, Volume: 71, Issue:7
Paw paw and cancer: annonaceous acetogenins from discovery to commercial products.
AID335294In vivo antitumor activity against mouse 3PS cells at 1.4 mg/kg relative to control
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's2 (50.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (33.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (12)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers [NCT02381470]Phase 258 participants (Actual)Interventional2019-02-11Completed
A Phase 1, Single-center, Randomized, 2-Way Cross-over, Open-label Study to Evaluate the Effect of Oral Repeated Doses of AZD1722 on the Pharmacokinetics of Oral Cefadroxil in Healthy Volunteers [NCT02140281]Phase 171 participants (Actual)Interventional2014-05-31Completed
Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial [NCT05977868]Phase 4135 participants (Anticipated)Interventional2023-08-04Enrolling by invitation
A Two-Way , Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Cefadroxil 500 mg Capsules Versus DURICEF® 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects. [NCT00835081]Phase 126 participants (Actual)Interventional2004-09-30Completed
Oral vs Intravenous Antibiotics for Treatment of Periprosthetic Joint Infection [NCT04723940]Phase 3308 participants (Anticipated)Interventional2021-01-25Enrolling by invitation
A RCT in Sweden of Acupuncture and Care Interventions for the Relief of Inflammatory Symptoms of the Breast During Lactation [NCT00405158]210 participants Interventional2002-01-31Completed
Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction [NCT01244698]Phase 4132 participants (Actual)Interventional2010-11-30Completed
A Two-Way Crossover, Open-Label, Single-Dose Fasting, Bioequivalence Study of Cefadroxil 500 mg Capsules Versus DURICEF® 500 mg Capsules in Normal Healthy Non-smoking Male and Female Subjects. [NCT00834275]Phase 126 participants (Actual)Interventional2004-09-30Completed
Antibiotic Prophylaxis in High-Risk Arthroplasty Patients [NCT04297592]Phase 44,618 participants (Anticipated)Interventional2020-06-11Enrolling by invitation
Comparative Randomized, Single Dose, Two-way Crossover, Open-label Study to Determine the Bioequivalence of Cefadroxil From Duricef 1 gm Film Coated Tablets (Smithkline Beecham Egypt, LLC Affiliated Co. to GalaxoSmithKline ) and Biodroxil 1 gm Film Coated [NCT02446496]Phase 424 participants (Actual)Interventional2014-03-31Completed
Comparative Pharmacokinetics and Pharmacodynamics (PK/PD) of Cefadroxil and Cephalexin for Pediatric Musculoskeletal (MSK) Infections [NCT03802552]Phase 117 participants (Actual)Interventional2019-05-01Completed
Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma) [NCT02479867]Phase 124 participants (Actual)Interventional2014-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00834275 (3) [back to overview]AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT00834275 (3) [back to overview]AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT00834275 (3) [back to overview]Cmax (Maximum Observed Concentration)
NCT00835081 (3) [back to overview]AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT00835081 (3) [back to overview]AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT00835081 (3) [back to overview]Cmax (Maximum Observed Concentration)
NCT02446496 (4) [back to overview]Apparent First-order Elimination or Terminal Rate Constant (Ke)
NCT02446496 (4) [back to overview]Maximal Measured Plasma Concentration (Cmax) After a Single Dose
NCT02446496 (4) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) and Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-infinity)
NCT02446496 (4) [back to overview]Time of the Maximum Plasma Concentration (T-max) and Terminal Half- Life (T-half)

AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on AUC0-inf. (NCT00834275)
Timeframe: Blood samples collected over a 12 hour period.

Interventionng*h/mL (Mean)
Cefadroxil (Test)52.303
Duricef® (Reference)51.770

[back to top]

AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on AUC0-t. (NCT00834275)
Timeframe: Blood samples collected over a 12 hour period.

Interventionng*h/mL (Mean)
Cefadroxil (Test)50.933
Duricef® (Reference)50.246

[back to top]

Cmax (Maximum Observed Concentration)

Bioequivalence based on Cmax. (NCT00834275)
Timeframe: Blood samples collected over a 12 hour period

Interventionng/mL (Mean)
Cefadroxil (Test)16.595
Duricef® (Reference)16.744

[back to top]

AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on AUC0-inf. (NCT00835081)
Timeframe: Blood samples collected over a 12 hour period.

Interventionng*h/mL (Mean)
Cefadroxil (Test)43.987
Duricef® (Reference)44.109

[back to top]

AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on AUC0-t. (NCT00835081)
Timeframe: Blood samples collected over a 12 hour period.

Interventionng*h/mL (Mean)
Cefadroxil (Test)42.656
Duricef® (Reference)42.685

[back to top]

Cmax (Maximum Observed Concentration)

Bioequivalence based on Cmax. (NCT00835081)
Timeframe: Blood samples collected over a 12 hour period.

Interventionng/mL (Mean)
Cefadroxil (Test)12.024
Duricef® (Reference)11.9

[back to top]

Apparent First-order Elimination or Terminal Rate Constant (Ke)

Plasma samples for PK analysis were drawn at indicated time points of each treatment period. Apparent first-order elimination or terminal rate constant calculated from a semi-log plot of the plasma concentration versus time curve. The parameter was calculated by linear least-squares regression analysis using the last three (or more) non-zero plasma concentrations. (NCT02446496)
Timeframe: Pre-dose (0.00) and 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 10.00 and 12.00 hours post-dose in each treatment period.

InterventionPer hour (Mean)
Treatment A-cefadroxil 1 gm0.30
Treatment B-cefadroxil 1 gm0.33

[back to top]

Maximal Measured Plasma Concentration (Cmax) After a Single Dose

Plasma samples for pharmacokinetic (PK) analysis were drawn at indicated time points of each treatment period. Cmax was defined as maximal measured plasma concentration over the time span specified. (NCT02446496)
Timeframe: Pre-dose (0.00) and 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 10.00 and 12.00 hours post-dose in each treatment period.

InterventionMicrogram per milliliter (Geometric Mean)
Treatment A-cefadroxil 1 gm28.18
Treatment B-cefadroxil 1 gm29.20

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) and Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-infinity)

Plasma samples for PK analysis were drawn at indicated time points of each treatment period. Area under the plasma concentration-time curve from time zero (0) to the last measurable concentration (t), as calculated by the linear trapezoidal method. Area under the plasma concentration-time curve from time zero (0) to infinity (AUC0-infinity) was calculated as the sum of the AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant (Ke), where first-order elimination or terminal rate constant calculated from a semi-log plot of the plasma concentration versus time curve. The parameter was calculated by linear least-squares regression analysis using the last three (or more) non-zero plasma concentrations. (NCT02446496)
Timeframe: Pre-dose (0.00) and 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 10.00 and 12.00 hours post-dose in each treatment period.

,
InterventionMicrogram.hour per milliliter (Geometric Mean)
AUC(0-t)AUC(0-infinity)
Treatment A-cefadroxil 1 gm106.55111.71
Treatment B-cefadroxil 1 gm102.21106.08

[back to top]

Time of the Maximum Plasma Concentration (T-max) and Terminal Half- Life (T-half)

Plasma samples for PK analysis were drawn at indicated time points of each treatment period. If the maximum value occurs at more than one point T-max was defined as the first time point with this value. The elimination or terminal half-life was calculated by dividing 0.693 (natural logarithm of 2) with lambda z, where lambda z is the terminal phase rate constant estimated by linear regression analysis of the log transformed concentration-time data after each single dose. (NCT02446496)
Timeframe: Pre-dose (0.00) and 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 10.00 and 12.00 hours post-dose in each treatment period.

,
InterventionHour (Median)
T-maxT-half
Treatment A-cefadroxil 1 gm1.502.28
Treatment B-cefadroxil 1 gm1.502.10

[back to top]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
palladium
Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46.		210metal allergen;
nickel group element atom;
platinum group metal atom
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		3.1410taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
4-hydroxy-25-desoxyneorollinicin
4-hydroxy-25-desoxyneorollinicin: isol from Rollina papilionella; structure given in first source		3.1410
acetogenins
Acetogenins: Polyketides of up to a few dozen carbons in length, formed by chain extension of multiple PROPIONATES and oxygenated to form tetrahydrofuran and lactone rings along the length of the chain. They are found in ANNONACEAE and other PLANTS. Related compounds cyclize to MACROLIDES.		2.0710
squamocin
squamocin: from seeds of Annona squamosa; a trihydroxy-bis-tetrahydrofuran fatty acid lactone; inhibits E. coli NADH:quinone oxidoreductase (NDH-1); structure given in first source		1.9810polyketide
ConditionIndicatedRelationship StrengthStudiesTrials